Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1‐year period.

Conventional systemic therapies can be highly risky or even contraindicated in elderly psoriatic patients, shifting physicians' attention to biologics.[1] However, efficacy and safety of biologics in patients >=65 years are not clearly described. We performed a retrospective observational study on moderate-to-severe plaque psoriasis elderly patients treated with ixekizumab for at least 1 year at the psoriasis care centre of University of Naples Federico II, Italy, analysing data from July 2017 to July 2019. The study population was represented by 16 elderly patients; mean psoriasis duration was of 39 ± 22 years with all patients being previously treated with at least one conventional systemic treatment (Table). [Extracted from the article]